Urine dna methylation markers for bladder cancer
AssigneeStichting VUmc
InventorsJacobus Adrianus Nieuwenhuijzen, Renske Daniëla Maria Steenbergen, Judith Bosschiether
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for detecting the presence of, or risk at, bladder cancer using novel DNA methylation markers for bladder cancer and to kits of parts useful in such methods.
Claims14
A method for classifying an individual as having bladder cancer or recurrent bladder cancer or being at risk of developing bladder cancer, the method comprising determining DNA methylation of at least a first gene or a promoter region thereof and a second gene or a promoter region thereof in a urine sample from said individual, wherein said genes are selected from the group consisting of GHSR, MAL, FAM19A4, PHACTR3, PRDM14, SST, ZIC1, miR-129, miR-148 and miR-935 and classifying said individual based on said DNA methylation.
A method for typing a urine sample from an individual, the method comprising determining DNA methylation of at least a first gene or a promoter region thereof and a second gene or a promoter region thereof in a urine sample from said individual, wherein said genes are selected from the group consisting of GHSR, MAL, FAM19A4, PHACTR3, PRDM14, SST, ZIC1, miR-129, miR-148 and miR-935 and typing said urine sample on the basis of DNA methylation.
A method for determining a treatment strategy for an individual, comprising determining DNA methylation of at least a first gene or a promoter region thereof and a second gene or a promoter region thereof in a urine sample from said individual, wherein said genes are selected from the group consisting of GHSR, MAL, FAM19A4, PHACTR3, PRDM14, SST, ZIC1, miR-129, miR-148 and miR-935, and determining a treatment strategy for said individual if determined DNA methylation indicates that said individual is having bladder cancer or recurrent bladder cancer or at risk of having bladder cancer.
A kit of parts comprising means for the detection of DNA methylation in at least a first gene or a promoter region thereof and a second gene or a promoter region thereof, wherein said genes are selected from the group consisting of GHSR, MAL, FAM19A4, PHACTR3, PRDM14, SST, ZIC1, miR-129, miR-148 and miR-935.
Use of a urine sample comprising a preservative, preferably ethylenediaminetetraacetic acid (EDTA), and optionally an antibiotic for analysis of DNA methylation of one or more genes or a promoter region thereof.
Dependencies are inferred from the claim text.